DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Important Safety Information for DIURIL® (Chlorothiazide) Oral Suspension
DIURIL® (Chlorothiazide) Oral Suspension is contraindicated in patients with anuria and patients with hypersensitivity to this product or to other sulfonamide-derived drugs.
DIURIL should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Thiazides may add to or potentiate the action of the other antihypertensive drugs.
Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.
The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.
Lithium generally should not be given with diuretics.
All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids.
If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy.
Thiazides have been shown to result in hypokalemia, dilutional hyponatremia, hyperuricemia, hyperglycemia, hypomagnesemia, decreased urinary calcium excretion, and increases in cholesterol and triglyceride levels. Patients should be monitored with laboratory testing and clinical symptoms.
It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman; however, thiazides cross the placental barrier and appear in cord blood. DIURIL should be used during pregnancy only if clearly needed.
In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required.
Hyperglycemia may occur with thiazide diuretics.
Adverse events of the greatest severity reported in the metabolic, cardiovascular, skin, gastrointestinal, renal, endocrine, urogenital, hematologic, and special senses body systems include: weakness, hypotension (including orthostatic hypotension), pancreatitis, aplastic anemia, anaphylactic reactions, electrolyte imbalance, muscle spasm, Erythema Multiforme (including Steven-Johnson Syndrome), exfoliative dermatitis (including Toxic Epidermal Necrolysis), transient blurred vision, and impotence.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.
For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
The information contained on this page is intended for US residents, healthcare providers, and pharmacists only.